Clinical Trial Update: Long Term Study With B2036-PEG [Phase 3]

View source ↗

Summary

Pfizer reports the long-term Phase 3 study of B2036-PEG in acromegaly has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• B2036-PEG

Snippet

Sponsor: Pfizer | Conditions: Acromegaly | Phase 3 | Status: COMPLETED